.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,137,994

« Back to Dashboard

Claims for Patent: 8,137,994

Title:Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
Abstract: The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: (a) NE metabolites, (b) NE/NE metabolites: dopamine/dopamine metabolites, (c) NE and serotonin, (d) NE/NE metabolites and serotonin, (e) NE and serotonin metabolites, (f) NE/NE metabolites and serotonin metabolites, or (g) NE is/are greater than about 30% over normal level; or dopamine/dopamine metabolites are less than about 30% below normal; or said patient has hypertriglyceridemai and/or hypertension . The present invention is also directed to treating identified patients with dopamine agonist therapy.
Inventor(s): Cincotta; Anthony H. (Tiverton, RI)
Assignee: VeroScience LLC (Tiverton, RI)
Application Number:13/066,280
Patent Claims: 1. A method of identifying patients to be treated by dopamine agonist therapy comprising the steps of: analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein one or more of: a) NE metabolites, b) NE or NE metabolites: dopamine or dopamine metabolites, c) NE and serotonin, d) NE or NE metabolites and serotonin, e) NE and serotonin metabolites, f) NE or NE metabolites and serotonin metabolites, or g) NE, is/are greater than about 30% over normal level; or dopamine or dopamine metabolites are less than about 30% below normal; or said patient is suffering from hypertriglyceridemia and/or hypertension.

2. The method of claim 1, wherein said patient is further suffering from a condition selected from the group consisting of cardiovascular disease, Type 2 diabetes, pre-diabetes, Metabolic Syndrome, obesity, hyperglycemia, glucose intolerance, hyperinsulinemia, insulin resistance, elevated plasma lipid levels, and combinations thereof.

3. A method of treating a patient suffering from a metabolic condition, comprising the steps of: (a) identifying patients to be treated by dopamine agonist therapy according to claim 1, and (b) administering to said identified patients a pharmaceutically effective regimen of dopamine agonist therapy; wherein said metabolic condition is selected from the group consisting of cardiovascular disease, Type 2 diabetes, pre-diabetes, Metabolic Syndrome, obesity, hyperglycemia, glucose intolerance, hyperinsulinemia, insulin resistance, elevated plasma lipid levels, and combinations thereof.

4. The method of claim 2, wherein said pharmaceutically effective regimen of dopamine agonist therapy comprises administration of bromocriptine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc